Recombinant syncytial pre-fusion f protein vaccine (rsvpref)
Brand: Abrysvo
PBAC's latest decision on Recombinant syncytial pre-fusion f protein vaccine (rsvpref): Noted (2024). Considered for Prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age by active immunisation of pregnant women between 28 and 36 weeks of gestation.
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
—
ICER not stated
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Pregnant women between 28 and 36 weeks of gestation (updated from 24-36 weeks per ATAGI advice) to prevent RSV-associated medically attended LRTI (MA-LRTI) and severe MA-LRTI in infants aged 0 to 6 months.
Therapy area
Vaccines
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
ORR
Key trials
Study 1008 (MATISSE), Study 1003 (SAVVY)
Comparator
Standard medical management of LRTI (no vaccine)
Economic model
CUA
ICER note
ICER value not stated in the provided PSD text. The document does not contain the complete economic analysis section required to extract numeric ICER values.